Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01943617Phase 4Completed

Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

Role: collaborator

NCT01938820Phase 4Completed

Optimized Treatment and Regression of HBV-induced Early Cirrhosis

Role: collaborator

NCT01938781Phase 4Completed

Optimized Treatment and Regression of HBV-induced Liver Fibrosis

Role: collaborator

NCT03108794Unknown

A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

Role: collaborator

NCT03131427Recruiting

China Registry for Genetic / Metabolic Liver Diseases

Role: collaborator

All 5 trials loaded